SAB Biotherapeutics Inc (SABS) Actualités

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

Raises combined $67.1M in private placement plus Tranche warrant exercise with syndicate of leading investors...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference

SIOUX FALLS, S.D., Nov. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a...

Form S-3 - Registration statement under Securities Act of 1933

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

SIOUX FALLS, S.D., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), today...

Form PRE 14A - Other preliminary proxy statements

SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Australian Human Research Ethics Committee (HREC) grants approval for SAB to begin first-in-human Phase 1...

Form D - Notice of Exempt Offering of Securities

Form 3 - Initial statement of beneficial ownership of securities

SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors

SIOUX FALLS, S.D., Oct. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage...